nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Generalised erythema—Cisplatin—urinary bladder cancer	0.141	0.141	CcSEcCtD
Cisatracurium Besylate—Hypoxemia—Gemcitabine—urinary bladder cancer	0.0629	0.0629	CcSEcCtD
Cisatracurium Besylate—Hypoxemia—Methotrexate—urinary bladder cancer	0.0322	0.0322	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Thiotepa—urinary bladder cancer	0.0236	0.0236	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Gemcitabine—urinary bladder cancer	0.0199	0.0199	CcSEcCtD
Cisatracurium Besylate—Laryngospasm—Etoposide—urinary bladder cancer	0.0144	0.0144	CcSEcCtD
Cisatracurium Besylate—Erythema—Mitomycin—urinary bladder cancer	0.013	0.013	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Etoposide—urinary bladder cancer	0.0123	0.0123	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Methotrexate—urinary bladder cancer	0.0121	0.0121	CcSEcCtD
Cisatracurium Besylate—Wheezing—Cisplatin—urinary bladder cancer	0.0114	0.0114	CcSEcCtD
Cisatracurium Besylate—Hypertension—Mitomycin—urinary bladder cancer	0.0113	0.0113	CcSEcCtD
Cisatracurium Besylate—Pruritus—Valrubicin—urinary bladder cancer	0.0109	0.0109	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Thiotepa—urinary bladder cancer	0.0104	0.0104	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Methotrexate—urinary bladder cancer	0.0102	0.0102	CcSEcCtD
Cisatracurium Besylate—Rash—Valrubicin—urinary bladder cancer	0.00975	0.00975	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Valrubicin—urinary bladder cancer	0.00974	0.00974	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Mitomycin—urinary bladder cancer	0.00949	0.00949	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Gemcitabine—urinary bladder cancer	0.00947	0.00947	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Cisplatin—urinary bladder cancer	0.00883	0.00883	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Fluorouracil—urinary bladder cancer	0.00857	0.00857	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Etoposide—urinary bladder cancer	0.00809	0.00809	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Fluorouracil—urinary bladder cancer	0.00795	0.00795	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Gemcitabine—urinary bladder cancer	0.00779	0.00779	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Etoposide—urinary bladder cancer	0.00744	0.00744	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.00741	0.00741	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Epirubicin—urinary bladder cancer	0.00688	0.00688	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Thiotepa—urinary bladder cancer	0.00684	0.00684	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Thiotepa—urinary bladder cancer	0.00681	0.00681	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00679	0.00679	CcSEcCtD
Cisatracurium Besylate—Rash—Mitomycin—urinary bladder cancer	0.00671	0.00671	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Mitomycin—urinary bladder cancer	0.00671	0.00671	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Etoposide—urinary bladder cancer	0.00665	0.00665	CcSEcCtD
Cisatracurium Besylate—Erythema—Thiotepa—urinary bladder cancer	0.00656	0.00656	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Doxorubicin—urinary bladder cancer	0.00636	0.00636	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00623	0.00623	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Cisplatin—urinary bladder cancer	0.00602	0.00602	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00581	0.00581	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Gemcitabine—urinary bladder cancer	0.00575	0.00575	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Gemcitabine—urinary bladder cancer	0.00573	0.00573	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00571	0.00571	CcSEcCtD
Cisatracurium Besylate—Convulsion—Thiotepa—urinary bladder cancer	0.00569	0.00569	CcSEcCtD
Cisatracurium Besylate—Hypertension—Thiotepa—urinary bladder cancer	0.00567	0.00567	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00555	0.00555	CcSEcCtD
Cisatracurium Besylate—Erythema—Gemcitabine—urinary bladder cancer	0.00552	0.00552	CcSEcCtD
Cisatracurium Besylate—Flushing—Cisplatin—urinary bladder cancer	0.00549	0.00549	CcSEcCtD
Cisatracurium Besylate—Erythema—Fluorouracil—urinary bladder cancer	0.00543	0.00543	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Cisplatin—urinary bladder cancer	0.00534	0.00534	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.00533	0.00533	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00525	0.00525	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Thiotepa—urinary bladder cancer	0.00523	0.00523	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Thiotepa—urinary bladder cancer	0.0052	0.0052	CcSEcCtD
Cisatracurium Besylate—Erythema—Cisplatin—urinary bladder cancer	0.00515	0.00515	CcSEcCtD
Cisatracurium Besylate—Flushing—Etoposide—urinary bladder cancer	0.00503	0.00503	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Etoposide—urinary bladder cancer	0.00491	0.00491	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Etoposide—urinary bladder cancer	0.00489	0.00489	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Etoposide—urinary bladder cancer	0.00488	0.00488	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00484	0.00484	CcSEcCtD
Cisatracurium Besylate—Hypertension—Gemcitabine—urinary bladder cancer	0.00477	0.00477	CcSEcCtD
Cisatracurium Besylate—Convulsion—Fluorouracil—urinary bladder cancer	0.0047	0.0047	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00467	0.00467	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00453	0.00453	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00451	0.00451	CcSEcCtD
Cisatracurium Besylate—Convulsion—Cisplatin—urinary bladder cancer	0.00446	0.00446	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00443	0.00443	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00442	0.00442	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Gemcitabine—urinary bladder cancer	0.00438	0.00438	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00435	0.00435	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00434	0.00434	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Fluorouracil—urinary bladder cancer	0.00432	0.00432	CcSEcCtD
Cisatracurium Besylate—Urticaria—Thiotepa—urinary bladder cancer	0.00425	0.00425	CcSEcCtD
Cisatracurium Besylate—Hypotension—Gemcitabine—urinary bladder cancer	0.00421	0.00421	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.0042	0.0042	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00419	0.00419	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Epirubicin—urinary bladder cancer	0.00417	0.00417	CcSEcCtD
Cisatracurium Besylate—Hypotension—Fluorouracil—urinary bladder cancer	0.00414	0.00414	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00412	0.00412	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Cisplatin—urinary bladder cancer	0.0041	0.0041	CcSEcCtD
Cisatracurium Besylate—Convulsion—Etoposide—urinary bladder cancer	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Cisplatin—urinary bladder cancer	0.00408	0.00408	CcSEcCtD
Cisatracurium Besylate—Hypertension—Etoposide—urinary bladder cancer	0.00407	0.00407	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00402	0.00402	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00399	0.00399	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00395	0.00395	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00395	0.00395	CcSEcCtD
Cisatracurium Besylate—Hypotension—Cisplatin—urinary bladder cancer	0.00392	0.00392	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Epirubicin—urinary bladder cancer	0.00387	0.00387	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.00386	0.00386	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00385	0.00385	CcSEcCtD
Cisatracurium Besylate—Pruritus—Thiotepa—urinary bladder cancer	0.00379	0.00379	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Etoposide—urinary bladder cancer	0.00375	0.00375	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Cisplatin—urinary bladder cancer	0.00374	0.00374	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Etoposide—urinary bladder cancer	0.00374	0.00374	CcSEcCtD
Cisatracurium Besylate—Hypotension—Etoposide—urinary bladder cancer	0.00359	0.00359	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Doxorubicin—urinary bladder cancer	0.00358	0.00358	CcSEcCtD
Cisatracurium Besylate—Urticaria—Fluorouracil—urinary bladder cancer	0.00352	0.00352	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Etoposide—urinary bladder cancer	0.00343	0.00343	CcSEcCtD
Cisatracurium Besylate—Rash—Thiotepa—urinary bladder cancer	0.00338	0.00338	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Thiotepa—urinary bladder cancer	0.00337	0.00337	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00326	0.00326	CcSEcCtD
Cisatracurium Besylate—Pruritus—Gemcitabine—urinary bladder cancer	0.00319	0.00319	CcSEcCtD
Cisatracurium Besylate—Pruritus—Fluorouracil—urinary bladder cancer	0.00313	0.00313	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00309	0.00309	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Epirubicin—urinary bladder cancer	0.00309	0.00309	CcSEcCtD
Cisatracurium Besylate—Urticaria—Etoposide—urinary bladder cancer	0.00306	0.00306	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00298	0.00298	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Methotrexate—urinary bladder cancer	0.00294	0.00294	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Methotrexate—urinary bladder cancer	0.00293	0.00293	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.00292	0.00292	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Doxorubicin—urinary bladder cancer	0.00286	0.00286	CcSEcCtD
Cisatracurium Besylate—Rash—Gemcitabine—urinary bladder cancer	0.00284	0.00284	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Gemcitabine—urinary bladder cancer	0.00284	0.00284	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Etoposide—urinary bladder cancer	0.00283	0.00283	CcSEcCtD
Cisatracurium Besylate—Erythema—Methotrexate—urinary bladder cancer	0.00282	0.00282	CcSEcCtD
Cisatracurium Besylate—Flushing—Epirubicin—urinary bladder cancer	0.00282	0.00282	CcSEcCtD
Cisatracurium Besylate—Rash—Fluorouracil—urinary bladder cancer	0.00279	0.00279	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Fluorouracil—urinary bladder cancer	0.00279	0.00279	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00276	0.00276	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Epirubicin—urinary bladder cancer	0.00275	0.00275	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Epirubicin—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00274	0.00274	CcSEcCtD
Cisatracurium Besylate—Pruritus—Etoposide—urinary bladder cancer	0.00272	0.00272	CcSEcCtD
Cisatracurium Besylate—Rash—Cisplatin—urinary bladder cancer	0.00265	0.00265	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Cisplatin—urinary bladder cancer	0.00265	0.00265	CcSEcCtD
Cisatracurium Besylate—Erythema—Epirubicin—urinary bladder cancer	0.00264	0.00264	CcSEcCtD
Cisatracurium Besylate—Flushing—Doxorubicin—urinary bladder cancer	0.00261	0.00261	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Doxorubicin—urinary bladder cancer	0.00255	0.00255	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00254	0.00254	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00253	0.00253	CcSEcCtD
Cisatracurium Besylate—Convulsion—Methotrexate—urinary bladder cancer	0.00245	0.00245	CcSEcCtD
Cisatracurium Besylate—Erythema—Doxorubicin—urinary bladder cancer	0.00244	0.00244	CcSEcCtD
Cisatracurium Besylate—Rash—Etoposide—urinary bladder cancer	0.00243	0.00243	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Etoposide—urinary bladder cancer	0.00242	0.00242	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00239	0.00239	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.0023	0.0023	CcSEcCtD
Cisatracurium Besylate—Convulsion—Epirubicin—urinary bladder cancer	0.00229	0.00229	CcSEcCtD
Cisatracurium Besylate—Hypertension—Epirubicin—urinary bladder cancer	0.00228	0.00228	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00226	0.00226	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Methotrexate—urinary bladder cancer	0.00224	0.00224	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00223	0.00223	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00216	0.00216	CcSEcCtD
Cisatracurium Besylate—Hypotension—Methotrexate—urinary bladder cancer	0.00215	0.00215	CcSEcCtD
Cisatracurium Besylate—Convulsion—Doxorubicin—urinary bladder cancer	0.00212	0.00212	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Cisatracurium Besylate—Hypertension—Doxorubicin—urinary bladder cancer	0.00211	0.00211	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Epirubicin—urinary bladder cancer	0.0021	0.0021	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Epirubicin—urinary bladder cancer	0.00209	0.00209	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00207	0.00207	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Methotrexate—urinary bladder cancer	0.00205	0.00205	CcSEcCtD
Cisatracurium Besylate—Hypotension—Epirubicin—urinary bladder cancer	0.00202	0.00202	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.002	0.002	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00196	0.00196	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Doxorubicin—urinary bladder cancer	0.00195	0.00195	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Doxorubicin—urinary bladder cancer	0.00194	0.00194	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Epirubicin—urinary bladder cancer	0.00192	0.00192	CcSEcCtD
Cisatracurium Besylate—Hypotension—Doxorubicin—urinary bladder cancer	0.00186	0.00186	CcSEcCtD
Cisatracurium Besylate—Urticaria—Methotrexate—urinary bladder cancer	0.00183	0.00183	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Doxorubicin—urinary bladder cancer	0.00178	0.00178	CcSEcCtD
Cisatracurium Besylate—Urticaria—Epirubicin—urinary bladder cancer	0.00171	0.00171	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.0017	0.0017	CcSEcCtD
Cisatracurium Besylate—Pruritus—Methotrexate—urinary bladder cancer	0.00163	0.00163	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Cisatracurium Besylate—Urticaria—Doxorubicin—urinary bladder cancer	0.00159	0.00159	CcSEcCtD
Cisatracurium Besylate—Pruritus—Epirubicin—urinary bladder cancer	0.00153	0.00153	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00147	0.00147	CcSEcCtD
Cisatracurium Besylate—Rash—Methotrexate—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Methotrexate—urinary bladder cancer	0.00145	0.00145	CcSEcCtD
Cisatracurium Besylate—Pruritus—Doxorubicin—urinary bladder cancer	0.00141	0.00141	CcSEcCtD
Cisatracurium Besylate—Rash—Epirubicin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Epirubicin—urinary bladder cancer	0.00136	0.00136	CcSEcCtD
Cisatracurium Besylate—Rash—Doxorubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Doxorubicin—urinary bladder cancer	0.00126	0.00126	CcSEcCtD
